http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017007956-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3dafa9257e99597f035013bf925d26a2 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55527 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K41-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K41-00 |
| filingDate | 2015-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8118ba2db126e0b15c9c83af826865cf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c812f4d879813ee0482d35194396edf1 |
| publicationDate | 2017-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2017007956-A |
| titleOfInvention | Treatment resistance reducing agent for treatment resistant cancer |
| abstract | The present invention provides a therapeutic resistance-reducing agent for therapeutic-resistant cancer, which can eliminate or reduce the therapeutic resistance of cancer, particularly drug resistance, and can enhance the effectiveness of cancer therapy. It is intended. The present invention provides a substance that specifically inhibits the binding between interleukin-34 and colony stimulating factor-1 receptor and / or a substance that suppresses the expression of interleukin-34 in cancer cells as an active ingredient. And a therapeutic resistance reducing agent for therapeutic resistant cancer. ADVANTAGE OF THE INVENTION According to this invention, the treatment tolerance of the cancer which shows tolerance with respect to treatment methods, such as anticancer agent administration or radiation irradiation, can be reduced, the effectiveness of cancer treatment is improved, and side effects etc. generate | occur | produce. Can be suppressed. [Selection] Figure 7 |
| priorityDate | 2015-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 71.